Haemonetics Corporation Haemonetics Corporation

Haemonetics Corporation

HAE

주식 순위 #3280
Haemonetics Corporation is a healthcare enterprise dedicated to providing... Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.
주가
$118.26
마지막 동기화: 2026-10-20
시가총액
$5.38B
변동 (1일)
-0.20%
변동 (1년)
131.02%
국가
US
거래 Haemonetics Corporation (HAE)

카테고리

Healthcare
Haemonetics Corporation (HAE)의 매출
Jun 2026 기준 매출 TTM: $1.35B
Haemonetics Corporation의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 $1.35B입니다. 2024년에 회사는 $1.31B의 수익을 올렸으며 이는 2023년의 $1.17B 대비 증가입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
Haemonetics Corporation의 수익 기록 (2000 ~ 2026)
매년 말 매출
연도 매출 변화
2026 (TTM) $1.35B -0.65%
2025 $1.36B 3.95%
2024 $1.31B 12.01%
2023 $1.17B 17.67%
2022 $993.20M 14.10%
2021 $870.46M -11.94%
2020 $988.48M 2.16%
2019 $967.58M 7.04%
2018 $903.92M 2.01%
2017 $886.12M -2.50%
2016 $908.83M -0.17%
2015 $910.37M -3.00%
2014 $938.51M 5.22%
2013 $891.99M 22.55%
2012 $727.84M 7.56%
2011 $676.69M 4.84%
2010 $645.43M 7.95%
2009 $597.88M 15.77%
2008 $516.44M 14.86%
2007 $449.61M 7.12%
2006 $419.73M 9.42%
2005 $383.60M 5.32%
2004 $364.23M 8.09%
2003 $336.96M 5.31%
2002 $319.97M 8.88%
2001 $293.86M 5.73%
2000 $277.92M 0.00%
유사 기업 또는 경쟁사의 매출
회사 매출 매출 차이 국가
$46.59B 3,345.60%
US
$35.48B 2,524.53%
IE
$25.84B 1,811.00%
US
$21.00B 1,452.94%
US
- -
DE